AMAG Pharmaceuticals, Inc. updated earnings guidance for the year 2017. For the year, the company expects GAAP net income of $88 - $44 million; interest expense of $71 million, operating loss in range of $72 million to income of $1 million; depreciation & intangible asset amortization of $127 million; non-GAAP adjusted EBITDA of $210-$260 million.